Lung ischemia-reperfusion injury (LIRI) is associated with many diseases, including primary graft dysfunction after lung transplantation, and has no specific and effective therapies. Necroptosis contributes to the pathogenesis of ischemia-reperfusion injury. Necrostatin-1 (Nec-1), the necroptosis inhibitor targeting RIPK1, has been reported to alleviate ischemia-reperfusion injury in various organs. However, the underlying mechanism of Nec-1 in LIRI remains unclear. In this paper, an in vivo LIRI model was built up by left lung hilar clamping in mice, and an in vitro cold ischemia-reperfusion (CI/R) model using BEAS-2B cells was applied to mimic the lung transplantation setting. We found Nec-1 significantly alleviated ischemia-reperfusion-induced lung injury, cytokine releasing, and necroptosis of epithelial cells in mouse lungs. In vitro, Nec-1 also mitigated CI/R-induced cell death and inflammatory responses in BEAS-2B cells, and these protective effects were achieved by simultaneously inhibiting the formation of necrosome and RIPK1-dependent apoptosis. However, Nec-1 decreased the necrosome number but increased the apoptosis level in lung tissues after ischemia reperfusion. We further clarified that Nec-1 could also attenuate lung injury by promoting neutrophil apoptosis from flow cytometry. In conclusion, Nec-1 alleviated lung ischemia-reperfusion injury by inhibiting necroptosis and apoptosis of epithelial cells and promoting the apoptosis of neutrophils. Thus, Nec-1 could be a promising medication against primary graft dysfunction after lung transplantation.
Background: Postoperative pain in thoracic surgery often requires opioids, yet can be poorly managed with short‐acting anesthetics. Liposomal bupivacaine (LB) offers prolonged analgesia, potentially improving pain control and reducing opioid use. This study evaluates LB’s effectiveness and safety in thoracic postoperative pain management, aiming to provide an alternative to current practices. Methods: In this single‐center, double‐blind, prospective, randomized controlled trial, patients undergoing uniportal lobectomy, segmentectomy, or wedge resection from November 2023 to May 2024 were enrolled. Participants were randomly assigned in a 1:1 ratio to receive either 0.375% ropivacaine (control group, n = 57) or LB (LB group, n = 56) for intercostal nerve blocks (ICNBs). Postoperative visual analog scale (VAS) scores, opioid consumption, overall benefit of analgesia score (OBAS), chest tube duration, length of hospital stay, and adverse events (AEs) were recorded and analyzed. Results: Data from 57 patients in the control group and 56 patients in the LB group were included in the analysis, with no significant demographic differences between the groups. The LB group demonstrated lower VAS scores at rest and during activity ( p > 0.05), reduced opioid consumption ( p = 0.021), and higher OBAS ( p < 0.01) compared with the control group. No significant differences were observed in chest tube duration, length of hospital stay, or AEs between the groups. Conclusion: LB is safe and effective for ICNB, providing significant postoperative pain relief for patients undergoing uniportal thoracoscopic surgery. Trial Registration: Chinese Registry of Clinical Trials: chiCTR2300075463
Background. ESCA is one of the digestive tract tumors with a high fatality. It is implicated in an intricate gene regulation process, but the pathogenesis remains ambiguous. Methods. The study used the packages of Limma from R software to analyze DEGs of ESCA in the GEO database and TCGA database. We employed the DAVID website for enrichment analysis, and the string database constructed the PPI network. Hub genes were identified from ESCA DEGs with Cytoscape MCODE. We evaluated the clinical relevance of LOX expression and its DNA methylation in the cBioPortal database and explored the roles of LOX in ESCA immunity, especially immune cell infiltration levels and immune checkpoint expression, by immunedeconv package of R software. Conclusions. The overexpression of LOX in ESCA is regulated by DNA hypomethylation; LOX overexpression or LOX hypomethylation can predict a worse prognosis in patients with ESCA. Besides, LOX may be involved in TIME regulation, promoting the infiltration levels and function of TAM. Hence, high LOX expression affected by DNA hypomethylation has an essential role in patients with ESCA, which may become an effective prognostic marker and therapeutic target.
11 May 2023 in Tropical Journal of Pharmaceutical Research
Purpose: To examine the potential modulatory mechanisms of NORAD in hepatoma in vitro. Methods: In this study, four human hepatoma cell lines (Bel7404, PLC5, HepG2, and HuH7), as well as a human immortalized Normal MIHA cell line were employed. Transfection was performed to up-or down-regulate NORAD and miR-202-5p expression in cells. RT-qPCR was used to measure expressions of NORAD, miR-202-5p, and biomarkers for cell cycle and apoptosis in HCC cell lines. CCK-8, Flow Cytometry for apoptosis and cell cycle arrest and Western blot experiments were performed to determine cellular viability, cell cycle arrest and apoptosis and related protein expressions. Bioinformatics tool was used to find possible binding sites on NORAD and miR-202-5p, which were further validated by dual-luciferase reporter gene assays. Results: NORAD adversely modulated miR-202-5p in hepatoma cells and mediated cell viability, apoptosis and cell cycle arrest through regulatingmiR-202-5p. Functional experiments revealed that downregulation of NORAD or upregulation of miR-202-5p suppressed cell viability and inhibited apoptosis and cell cycle arrest. Silenced NORAD regulated the EGFR/PI3K/AKT pathway via enhancing miR-202-5p expression in HCC cell lines.Conclusion: NORAD interaction with miR-202-5p mediated the EGFR/PI3K/AKT network.